Wave Life Sciences Ltd. announced the completion of dosing in the first two cohorts of the INLIGHT trial for the obesity treatment WVE-007, with clinical data expected in the second half of 2025. The ...

Wave Life Sciences announced WVE-007, an siRNA treatment for obesity aimed at silencing INHBE to promote sustainable weight loss. Wave Life Sciences has announced the submission of a clinical trial ...

January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences ...

SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...

Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in ...

Discover Manthan 2026, a premier symposium by VASUs Foundation aimed at elevating India's role in life sciences research and ...

BOSTON, MA, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- During JPM Week 2026, Hill Research released a new ...

New Jersey is emerging as a national leader in AI-driven life sciences, transforming health care, drug discovery and ...

Builds on existing partnership by further leveraging the combined power of real-world data, real-world evidence and privacy-preserving record linkage technology to help solve key clinical trial ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Ribo Life Science Co., Ltd. ('Ribo' or the 'Company', stock code: 06938.HK), a leading company in small interfering RNA ...